Dexcom is launching a new, lower-cost continuous glucose monitor in Germany to challenge the 75% market share of traditional test strips from Roche and Ascensia.
Dexcom (Nasdaq: DXCM) will soon launch its Flex continuous glucose monitoring system in Germany, a strategic move to capture a share of the country's 11 million-person diabetes market currently dominated by traditional fingerprick tests. The new system is designed specifically for adults with Type 2 diabetes who do not use intensive insulin therapy, opening a significant new front in the battle for glucose monitoring supremacy against rivals Roche, Ascensia, and Abbott.
"Launching Dexcom Flex in Germany reflects our continued focus on expanding access to CGM," Alexander Fröhlich, vice president and general manager for the DACH region at Dexcom, said in a statement. "As personalization becomes increasingly important in Type 2 diabetes care, Flex enables a more tailored approach to glucose monitoring."
Unlike intensive CGM systems, Dexcom Flex is tailored for patients using basal insulin, oral medications, or GLP-1 receptor agonists. It provides real-time glucose readings to a smartphone without the need for routine fingerpricks, aiming to give users and their doctors a clearer picture of how diet, activity, and medication affect glucose levels. The launch comes as Germany is expanding its use of digital health tools, creating a favorable environment for Dexcom's new offering.
The move is critical for Dexcom as it seeks new growth avenues beyond the intensive insulin-dependent population. Germany represents Europe's largest single market for blood glucose monitoring, but it remains a stronghold for traditional strip-based meters, which account for an estimated 2-3 billion test strip sales annually. By introducing a CGM system tailored for this less intensive, but far larger, patient group, Dexcom is directly challenging the profitable "razor-and-blade" economic model that has sustained incumbents for decades.
Cracking the €1.5 Billion Test Strip Market
The German glucose monitoring market is a mature and concentrated landscape. Roche Diabetes Care, with its Accu-Chek brand, and Ascensia Diabetes Care, with its Contour products, command a combined 70-75% share of the pharmacy channel. According to a 2026 market report from IndexBox, the average retail price for a branded test strip ranges from €0.50 to €0.80, making the consumable strip market a lucrative, high-volume business.
Dexcom's Flex aims to disrupt this model by offering a more comprehensive, data-rich solution. While traditional meters provide a single snapshot in time, CGM systems track glucose levels continuously, offering trend data and alerts that can help prevent hypoglycemic events. Studies have shown that CGM use in people with Type 2 diabetes can support reductions in diabetes-related hospitalizations and long-term complications. The launch also navigates a complex regulatory environment, as the European In Vitro Diagnostic Regulation (IVDR) has increased the cost of bringing new test strip systems to market by an estimated €1-3 million per kit.
A Stepping Stone to Broader CGM Adoption
The Flex launch is a key part of Dexcom's broader global strategy outlined at its recent investor day. The company is awaiting the results of its pivotal CONNECT trial on June 6, which is studying A1C reduction in people with type 2 diabetes not using insulin. Positive results could serve as an "anchor" for expanding CGM access for all people with diabetes in the U.S. and internationally, potentially unlocking Medicare coverage that would add 12 million covered lives.
Management sees Flex as part of a portfolio approach to different markets. While its premium G-series products serve markets with broad reimbursement, Flex is designed for markets with more limited or tiered reimbursement for non-intensive patients. The company is also working on its next-generation G8 platform, which it says will be 50% smaller than the current G7 sensor and is slated for submission next year. For investors, Dexcom's push into the non-intensive type 2 market represents a significant expansion of its total addressable market, with the company projecting global covered lives to grow from 23 million this year to 52 million by the end of its long-range plan.
This article is for informational purposes only and does not constitute investment advice.
